uiux
Regular
New Research Collaboration with BrainChip for SARS-CoV-2 Antibody Detection
Perth, Australia April 5, 2021 – BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology...
www.biotome.com.au
Perth, Australia April 5, 2021 – BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology company Biotome Pty Ltd. Biotome is developing highly accurate antibody tests for infections.
The Akida neuromorphic processor chip will be used to interpret sensor responses and to find out which responses are the most representative for antibodies that are protective. The objective of the Biotome research project is to create a handheld device that uses nanomaterial-based sensors in combination with the Akida chip that will give accurate results in seconds.
Dr. Samuel Lundin, CEO of Biotome said: “We believe the precision of antibody tests for infections can be improved dramatically. Our partnership with Brainchip is an important step for our development of point-of-care tests that are based on patented high-precision immunological markers. We are very excited to explore how the cutting-edge Akida neural processor can improve the accuracy and information quality of the antibody-tests we are developing, by providing advanced AI capacity at the point of care. The joint project we are embarking on aims to use Akida to identify the antibodies that can protect against SARS- CoV-2 infection - the so-called neutralising antibodies. If the project is successful we will apply the same principles to other antibody tests in our pipeline.”
Peter van der Made, Interim CEO of BrainChip Ltd said: “The use of the Akida neuromorphic processor in antibody detection and other medical diagnostic tools is a testimony to our efforts to help in the development of beneficial Artificial Intelligence applications around our chip. Our focus is the Akida neuromorphic processor, and we are a silicon manufacturer, but we are assisting our clients in bringing advanced AI products to market”.
---
Next Generation Antibody Diagnostics | Biotome
At Biotome, we are developing next generation antibody diagnostics that unlock the high-resolution of the immune system. Our efficient, scalable discovery pipeline is applicable to a huge number of diseases.
www.biotome.com.au
Technology | Biotome
www.biotome.com.au
Our Covitope test for SARS-CoV-2 will return greater detail than current tests, distinguishing disease severity and identifying protective antibodies. It will provide individuals with information on infection- or vaccine-induced protection levels, allowing them to safely plan gatherings, travel or booster vaccinations.
